Outcome of chronic granulomatous disease - conventional treatment versus stem cell transplantation.



Dedieu, Cinzia, Albert, Michael H, Mahlaoui, Nizar, Hauck, Fabian, Hedrich, Christian ORCID: 0000-0002-1295-6179, Baumann, Ulrich, Warnatz, Klaus, Roesler, Joachim, Speckmann, Carsten, Schulte, Johannes
et al (show 4 more authors) (2020) Outcome of chronic granulomatous disease - conventional treatment versus stem cell transplantation. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

Access the full-text of this item by clicking on the Open Access link.

Abstract

BACKGROUND:Hematopoietic stem cell transplantation (HSCT) can cure chronic granulomatous disease (CGD), but it remains debated whether all conventionally treated CGD-patients benefit from HSCT. METHODS:We retrospectively analyzed 104 conventionally treated CGD-patients, of whom 50 patients underwent HSCT. RESULTS:On conventional treatment, 7 patients (13%) died after a median time of 16.2 years (interquartile range (IQR) 7.0-18.0). Survival without severe complications was 10±3% (mean±SD) at the age of 20 years; 85% of patients developed at least one infection, 76% one non-infectious inflammation. After HSCT, 44 patients (88%) were alive at a median follow-up of 2.3 years (IQR 0.8-4.9): Six patients (12%) died from infections. Survival after HSCT was significantly better for patients transplanted ≤ 8 years (96±4%) or for patients without active complications at HSCT (100%). Eight patients suffered from graft failure (16%), six (12%) developed acute graft-versus-host disease requiring systemic treatment. Conventionally treated patients developed events that required medical attention at a median frequency of 1.7 (IQR 0.8-3.2) events per year versus 0 (IQR 0.0-0.5) in patients beyond the first year post-HSCT. While most conventionally treated CGD-patients failed to thrive, catch-up growth after HSCT in surviving patients reached the individual percentiles at the age of diagnosis of CGD. CONCLUSION:CGD-patients undergoing HSCT until 8 years of age show excellent survival, but young children need more intense conditioning to avoid graft rejection. Risks and benefits of HSCT for adolescents and adults must still be weighed carefully.

Item Type: Article
Depositing User: Symplectic Admin
Date Deposited: 25 Nov 2020 10:31
Last Modified: 12 Jun 2021 16:14
DOI: 10.1111/pai.13402
Open Access URL: https://onlinelibrary.wiley.com/doi/10.1111/pai.13...
URI: https://livrepository.liverpool.ac.uk/id/eprint/3108182